N-terminal Modified Exendin-4 for Diabetes Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide drugs, such as GLP-1 and exendin-4, have low stability and short half-life due to proteolytic degradation, leading to frequent administration needs and reduced therapeutic efficacy, with existing modifications often compromising receptor affinity and activity.
Innovation Solution
Development of N-terminal amino acid-modified exendin-4 derivatives, including desamino-histidyl, beta-hydroxy imidazopropionyl, beta-carboxylmidazopropionyl, dimethyl-histidyl, and imidazoacetyl-exendin-4, which enhance blood stability and insulinotropic activity by modifying the N-terminal histidine residue, thereby increasing resistance to dipeptidyl peptidase and maintaining receptor affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If the N-terminal histidine residue of exendin-4 is modified to increase resistance to dipeptidyl peptidase, then blood stability is improved, but receptor affinity is markedly reduced
Solution Approach 1:
The patent applies parameter changes by systematically varying the chemical structure at the N-terminal position of exendin-4. Specifically, it modifies the histidine residue through different chemical transformations (N-methylation, alpha-methylation, imidazole substitution) to find the optimal balance between protease resistance and receptor affinity. The patent identifies that while complete N-terminal modification improves stability, it reduces activity, so the invention optimizes the degree and type of modification to achieve both stability and activity.
Solution Approach 2:
The patent applies local quality by making targeted modifications only at the N-terminal histidine residue position while leaving the rest of the peptide sequence intact. This localized modification approach allows the invention to improve blood stability at the specific site vulnerable to dipeptidyl peptidase degradation without disrupting the overall structure and function of the peptide. The modification is confined to a specific local region (the N-terminal residue) rather than the entire molecule.
2Reliability
If peptide drugs are administered frequently to maintain blood level and titer, then therapeutic efficacy is maintained, but patient pain and burden increase
Solution Approach 1:
The patent applies partial or excessive action by extending the duration of drug action through structural modification. By modifying the N-terminal histidine residue to resist degradation, the peptide maintains therapeutic blood levels for a longer period, effectively reducing the frequency of administration needed. This allows the drug to exert its effect for an extended time, thereby reducing the number of administrations required to maintain therapeutic efficacy.
3Ease of operation
If peptide drugs are administered by inhalation to avoid injection pain, then patient comfort is improved, but in-vivo transfer efficiency is remarkably lower
Solution Approach 1:
The patent applies parameter changes by modifying the chemical parameters of the peptide to enhance its stability and resistance to degradation. By changing the N-terminal residue structure, the peptide becomes more resistant to enzymatic breakdown, which improves its ability to maintain therapeutic levels regardless of the administration route. This parameter modification makes the peptide more suitable for non-injectable routes by improving its stability profile.
Data Source
AI summary
The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases.